The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Chiasma disavows any obligation to update the information contained in such press releases after the date of their issuance.
|01/09/17||Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017|
|WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate review of 2016 and preliminary outlook for 2017.
“2016 was a challenging year for Chiasma due to our receipt of a Complete Response Letter for Mycapssa from the FDA at the time of our PDUFA date in April 2016. Despite this setback, we remain committed to developing new treatmen... |
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.